Skip to main content

Table 2 Antimicrobial resistance in Polish ICUs by VAP, 2013–2015

From: Epidemiology of Ventilator-Associated Pneumonia, microbiological diagnostics and the length of antimicrobial treatment in the Polish Intensive Care Units in the years 2013-2015

  Number of isolates Antibiotic or resistant codes Non susceptible N (%)
Gram-positive cocci
Staphylococcus aureus 27 MRSA 2 (7.4)
ampicillin 0 (0)
glycopeptides 0 (0)
Enterobacteriaceae
Escherichia coli 12 ampicillin 7 (58.3)
ceftazidime 3 (25.0)
cefotaxim/ceftriaxone 3 (25.0)
imipenem 1 (8.3)
meropenem/doripenem 0 (0)
ESBL 1 (8.3)
Klebsiella pneumoniae 31 ampicillin 28 (90.3)
ceftazidime 22 (71.0)
cefotaxim/ceftriaxone 23 (74.2)
imipenem 0 (0)
meropenem/doripenem 0 (0)
ESBL 15 (48.4)
Non-fermenting Gram-negative bacteria
Acinetobacter baumannii. 34 imipenem 24 (70.6)
meropenem/doripenem 18 (52.9)
colistin 0 (0.0)
sulbactam 14 (41.2)
Pseudomonas aeruginosa 10 piperacillin 2 (20.0)
ceftazidime 2 (20.0)
colistin 0 (0.0)
imipenem 2 (20.0)
meropenem/doripenem 2 (20.0)
  1. ESBL Extended Spectrum Beta-lactamase, MRSA methicillin-resistant Staphylococcus aureus, VAP Ventilator-Associated Pneumonia